IP Library Granted Patent US 9,714,433
Granted Patent B2
US 9,714,433 · App. 14/195,698 · Granted Jul 25, 2017

Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue

Inventors: Kazuhiro Sakurada (Kanagawa, JP); Tetsuya Ishikawa (Tokyo, JP); Hideki Masaki (Tokyo, JP); Shunichi Takahashi (Hyogo, JP)
Assignee: KYOTO UNIVERSITY
C12N15/85C12N5/0696C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2510/00C12N2799/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,714,433
App. No.
14/195,698
Granted
Jul 25, 2017
Kind
B2
Abstract

Establishment of human pluripotent stem cells having properties close to human ES cells with the genome of the patient per se that can circumvent immunological rejection of transplanted cells from cells derived from a postnatal human tissue are described. Human pluripotent stem cells can be induced by introducing three genes of Oct3/4, Sox2 and Klf 4, or three genes of Oct3/4, Sox2 and Klf 4 plus the c-Myc gene or a histone deacetylase (HDAC) inhibitor of undifferentiated stem cells present in various human postnatal tissues in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation.

Claims (4)

1. A method for generating a human pluripotent stem cell, comprising the steps of:

(i) introducing one or more retroviral vectors comprising a gene encoding Oct3/4, a gene encoding Sox2 and a gene encoding Klf4 into an isolated human post-natal cell; and

(ii) culturing the cell of step (i) in the presence of an inhibitor of Rho kinase and/or a histone deacetylase inhibitor under conditions that maintain pluripotency and self-renewal, thereby generating a human pluripotent stem cell.

2. The method of claim 1 , wherein the inhibitor of Rho kinase is Y-27632 or HA-1077.

Priority Claims (1)
JP 2007-159382 · Jun 15, 2007 · national
Continuity (2)
Division 12663840
Related Publication 20140206083A1 · Jul 24, 2014